Latest Articlesddd

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

July 11, 2024 0

Kazia Therapeutics in the NEWS  Sydney, July 10, 2024, Kazia Therapeutics Limited (KZIA) - an oncology-focused …

Illumina Acquired Fluent BioSciences to Accelerate Single-Cell Analysis and Discovery to a Broader Customer Base

July 10, 2024 0

Illumina Inc The latest take over by Illumina, Inc. (ILMN) has been a company with advanced …

Advanced Micro Devices to Buy the Largest Private AI Lab in Europe

July 10, 2024 0

Advanced Micro Devices in the NEWS  Advanced Micro Devices (AMD) today announced the signing of a …

The European Commission Approved Regeneron Product Dupixent® as Maintenance Treatment for Adults with Uncontrolled COPD

July 5, 2024 0

Regeneron in the NEWS Regeneron Pharmaceuticals (REGN) and Sanofi (SNY . . . This content is …

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat

July 2, 2024 0

Merck in the NEWS Merck Pharmaceuticals (MRK), known as Merck, Sharp & Dohme (MSD) outside the …

SCG Cell Therapy: FDA Approved IND Application of Product SCG142 to Initiate Phase 1/2 Clinical Trial for A Next Generation HPV and its cancers.

July 1, 2024 0

SCG Cell Therapy FDA Approval SCG Cell Therapy Pte Ltd (SCG) is a biotech company developing …

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612 in Parkinson’s Disease at 10th Congress of the European Academy of Neurology  

June 28, 2024 0

From Mitsubishi Tanabe Pharma America Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at …

Verona Pharma Announces the US FDA Approval of Ohtuvayre™ for the Maintenance Treatment of COPD

June 27, 2024 0

Verona Pharma in the NEWS Yesterday, June 26, 2024, Verona Pharma plc (VRNA) announced that the …

Nurix Therapeutics: Positive Results from Ongoing Clinical Trial of NX-5948

June 25, 2024 0

Nurix Therapeutics in the NEWS On June 16, 2024, Nurix Therapeutics (NRIX) announced the presentation of …

FDA Approval of argenx Product VYVGART Hytrulo for Patients with CIDP

June 24, 2024 0

argenx in the NEWS argenx SE (ARGX) announced that the U.S. FDA has approved VYVGART Hytrulo …

Alnylam Pharmaceuticals: Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran

June 24, 2024 0

Alnylam Pharamceuticals Announcement June 24, 2024, Alnylam Pharmaceuticals (ALNY) announced positive topline results from its HELIOS-B …

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients

June 21, 2024 0

Sarepta Therapeutics in the NEWS On June 20, 2024, Sarepta Therapeutics (SRPT) announced that the U. …

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

June 20, 2024 0

Gilead Sciences' Lenacapavir Demonstrated 100% Efficacy in Preventing HIV Gilead Sciences, Inc. (GILD) today announced topline …

Altimmune Important Upcoming Presentations

June 18, 2024 0

Altimmune Today, June 18, 2024, Altimmune (ALT) announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual …

RegenxBio Announced Completion of a Successful Pre-BLA Meeting with the FDA for RGX-121 for Mucopolysaccharidosis Type II

June 18, 2024 0

RegenxBio Today RegenxBio (RGNX) announced it completed a successful Pre-Biologics License Application (BLA) meeting with the …

 AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin and Paclitaxel followed by IMFINZI Monotherapy for Adults with Primary Advanced or Recurrent Endometrial Cancer

June 17, 2024 0

US FDA Approval for AstraZeneca’s IMFINZI AstraZeneca (AZN): The trial results of the FDA newly approved …

Broadcom Inc. Announces 2Q Fiscal Year 2024 Financial Results, Quarterly Dividend and Stock Split 10-1

June 14, 2024 0

Broadcom Inc Announcements What analysts heard from the Artificial Intelligence (AI) firm Broadcom Inc is promising …

ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer

June 13, 2024 0

Innovent Biologics Announcement at ASCO Innovent Biologics , Inc. (HKEX: 01801)(OTC: IVBXF) announced that the clinical . …

Eli Lilly Product Tirzepatide Has Impressive Clinical Trial Results Treating MASH

June 10, 2024 0

Eli Lilly in the NEWS Eli Lilly and Company (LLY) announced detailed results from the SYNERGY-NASH …

Gilead Sciences and Arcus Biosciences: Treating Gastrointestinal Cancers

June 6, 2024 0

Gilead Sciences and Arcus Biosciences in the NEWS Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced …